Menu
News
Ibogaine
Ketamine
LSD
MDMA
Psilocybin
Resources
Research Hubs
Studies and Reports
Provider Directory
Terminology
Opinion
Events
About Us
Compass Pathways
Compass Pathways COMP360 Delivers on Phase 2 Results
May
9
,
2024
Compass Pathways Forges Research Collaboration with Hackensack Meridian Health
January
19
,
2024
Compass Pathways Appoints Teri Loxam as CFO
December
15
,
2023
Compass Pathways Psilocybin Trial Shows 80% Remission Rate in Bipolar II Disorder
December
7
,
2023